Ubrogepant continues to show benefit for migraine, subgroup analyses show
20 May 2021
byAudrey Abella
Subgroup analyses of the ACHIEVE I and II studies presented at AAN 2021 continued to demonstrate favourable outcomes associated with the 50-mg dose of the FDA-approved oral CGRP* receptor antagonist ubrogepant for acute treatment of migraine in adults, particularly among those who were classified as “triptan-insufficient responders”**. Its safety and tolerability were also consistent across various demographic and clinical characteristic subgroups.
Ubrogepant continues to show benefit for migraine, subgroup analyses show
20 May 2021
